Kobayashi Pharmaceutical receives JPY 500 billion proposal for Kobayashi Pharma stock

Published on 10/13/2026 at 07:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kobayashi Pharmaceutical received a nonbinding proposal on September 25, 2026. Kobayashi Pharma stock was JPY 7,180.00, 1.46 percent below its high.

Key points in brief

Kobayashi Pharmaceutical received a nonbinding take-private proposal dated September 25, 2026.
The reported proposal exceeds JPY 500.0 billion, while fiscal 2025 net income fell to JPY 3.7 billion.
The stock was JPY 7,180.00 on October 13, 2026, below its JPY 7,286.00 52-week high.
The next reported earnings date is November 10, 2026.

Kobayashi Pharma, JP3301100008, Illustration mit AI erstellt.

Kobayashi Pharmaceutical (JP3301100008) received a preliminary, nonbinding proposal to take the company private on September 25, 2026. Reuters reported that the potential transaction could exceed JPY 500.0 billion and involve CVC Capital Partners and Nippon Sangyo Suishin Kiko.

Three dated signals for investors

On February 10, 2026, Kobayashi Pharmaceutical reported fiscal 2025 revenue of JPY 165.7 billion, operating income of JPY 14.9 billion and net income of JPY 3.7 billion. M&A Strategy News said net income fell 63.7 percent from the previous fiscal year, while revenue increased 0.1 percent.

On August 6, 2026, the company reported second-quarter revenue of JPY 37.1 billion and net income of JPY 100.0 million for the six months ended June 30, 2026. Investing.com also lists revenue of JPY 35.4 billion in the prior quarter, making the latest figure 4.83 percent higher on a quarter-over-quarter basis.

On September 25, 2026, the reported JPY 500.0 billion transaction scale stood above the companys market capitalization of about JPY 460.0 billion cited in deal coverage. The comparison frames the proposal as a corporate-value discussion rather than a completed tender offer.

What does the proposal change?

The proposal places governance, quality-control recovery and transaction terms at the center of the investment case. Reuters described the bid as a potential take-private transaction, while the company disclosure cited in current coverage characterized the proposal as preliminary and nonbinding.

Dates and market position

Finranks lists November 10, 2026 as the next earnings date. The event follows the June 30, 2026 half-year reporting period and gives investors a scheduled checkpoint for profitability and cash generation.

On October 13, 2026, Kobayashi Pharmaceutical was trading at JPY 7,180.00 on the Tokyo Stock Exchange, down JPY 58.00 from the previous session and 1.46 percent below its JPY 7,286.00 52-week high. Its market capitalization was JPY 533.8 billion, while the 52-week range was JPY 5,030.00 to JPY 7,286.00.

The further course of trading is shown by the continuously updated real-time quote of Kobayashi Pharma stock.